Table 1.

Demographic features and baseline characteristics of the study groups

	Donepezil group	Placebo group
Type of multiple sclerosis disease (n (%))
Relapsing remitting	41 (82%)	44 (88%)
Primary progressive	3 (6%)	2 (4%)
Secondary progressive	6 (12%)	4 (8%)
Relapse rate (n (%))
Without relapse	39 (78%)	38 (76%)
Once	8 (16%)	10 (20%)
Twice	3 (6%)	2 (4%)
Duration of multiple sclerosis (years)	6.15	5.90
Age	31.92±5.89	30.66±5.43
Female/male	37 (74%)/13 (26%)	34 (68%)/16 (32%)
Extended disability scale score (mean)	2.71	2.58
Disease modifying therapy
Fingolimod	5 (10%)	7 (14%)
Beta interferon	43 (86%)	41 (82%)
Rituximab	2 (4%)	2 (4%)
Dominant disease symptom
Motor	22 (44%)	20 (40%)
Brain stem	10 (20%)	11 (22%)
Sensory	7 (14%)	8 (16%)
Sphincteric	6 (12%)	7 (14%)
Ocular	5 (10%)	4 (8%)